Group 1 - The company, 加科思-B (01167), announced a share buyback plan, intending to repurchase 72,000 shares at a total cost of HKD 498,300 [1]

Core Viewpoint - The company, 加科思-B (01167), announced a share buyback plan, indicating a strategic move to enhance shareholder value through the repurchase of its own shares [1] Group 1 - The company will spend HKD 498,300 to repurchase 72,000 shares [1]

Group 1 - The company, 加科思-B (01167.HK), announced a share buyback plan on November 13, 2025, involving an expenditure of HKD 500,000 to repurchase 72,000 shares [1] - The buyback price per share is set between HKD 6.92 and HKD 6.93 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 加科思藥業集團有限公司 呈交日期： 2025年11月13日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01167 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 目 ...

Summary of Key Points Core Viewpoint - A total of 30 companies conducted share buybacks on November 12, 2025, with China COSCO Shipping Holdings (01919) leading in terms of buyback amount and quantity. Group 1: Buyback Details - China COSCO Shipping Holdings (01919) repurchased 3 million shares for a total of 43.1382 million yuan, representing 0.770% of its total share capital [1][2] - Sinopec Limited (00386) repurchased 3.708 million shares for 16.5210 million yuan, accounting for 0.110% of its total share capital [2] - China International Marine Containers (02039) repurchased 2 million shares for 14.1189 million yuan, which is 1.090% of its total share capital [2] Group 2: Other Notable Buybacks - China Feihe Limited (06186) repurchased 2 million shares for 8.8511 million yuan, representing 1.074% of its total share capital [2] - AAC Technologies Holdings (02018) repurchased 221,500 shares for 8.8302 million yuan, which is 0.186% of its total share capital [2] - Linklogis Inc. (09959) repurchased 1,208,000 shares for 3.7894 million yuan, accounting for 4.685% of its total share capital [2] Group 3: Additional Companies - Mobi Development (00947) repurchased 50,000 shares for 8.0500 million yuan, which is 0.222% of its total share capital [3] - Tianfu (06868) repurchased 10,000 shares for 30,000 yuan, representing 0.051% of its total share capital [3] - Hylink Digital Solutions (01586) repurchased 80,000 shares for 22,100 yuan, accounting for 4.305% of its total share capital [3]

Core Viewpoint - The company is establishing a Co-Chief Executive Officer (Co-CEO) system to enhance its global strategy and operational efficiency, with Dr. Andrea Wang-Gillam appointed as Co-CEO effective November 12, 2025 [1] Group 1: Leadership Changes - Dr. Andrea Wang-Gillam, currently the Chief Medical Officer, will transition to the role of Co-CEO [1] - Dr. Wang-Gillam has over 20 years of experience as an oncologist in the U.S. and is recognized as an expert in gastrointestinal oncology [1] Group 2: Strategic Implications - The establishment of the Co-CEO role is a significant step in the company's global strategy, aiming to create a collaborative model of "global strategic coordination + regional deep cultivation" [1] - This strategic adjustment is expected to generate greater value for the company's shareholders [1]

Core Viewpoint - The company is advancing its global strategy by establishing a Co-Chief Executive Officer (Co-CEO) system to enhance cross-regional operational efficiency [1] Group 1 - The board of directors has approved the establishment of the Co-CEO system [1] - Dr. Andrea Wang-Gillam, currently the Chief Medical Officer, will be appointed as Co-CEO effective November 12, 2025 [1]

Core Viewpoint - The company is implementing a Co-Chief Executive Officer (Co-CEO) system to enhance its global strategy and operational efficiency, with Dr. Andrea Wang-Gillam appointed as Co-CEO effective November 12, 2025 [1] Group 1: Leadership Changes - Dr. Andrea Wang-Gillam, currently the Chief Medical Officer, has been appointed as Co-CEO, bringing over 20 years of experience in oncology and a deep understanding of international clinical trial regulations and commercialization [1] - The introduction of the Co-CEO system is part of the company's strategy to create a collaborative model that integrates global strategic oversight with regional operational execution [1] Group 2: Strategic Implications - This leadership adjustment is a significant step in advancing the company's globalization strategy, aimed at creating greater value for shareholders [1]

（ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：1167） 委任聯席首席執行官 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 JACOBIO PHARMACEUTICALS GROUP CO., LTD. 加 科 思 藥 業 集 團 有 限 公 司 本公告由加科思藥業集團有限公司（「本公司」或「加科思」，連同其附屬公司，統稱「本集 團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.51(2)條發佈。 本公司董事（「董事」）會（「董事會」）欣然宣佈，為進一步推進本集團全球化戰略佈局，提 升跨區域運營效率，經董事會審議通過，本公司將設立「聯席首席執行官」（Co-Chief Executive Officer，簡稱「聯席CEO」）制度。Andrea Wang-Gillam（王宜）（「王宜」）博士，現 任首席醫學官（Chief Medical Officer，簡稱「CMO」），於2025年11月12日被董事會任 ...

相关事件 加科思-B(01167.HK)11月12日耗资49万港元回购7.2万股 加科思-B(01167.HK)11月11日耗资48.2万港元回 购7.2万股 格隆汇11月12日丨加科思-B(01167.HK)发布公告，2025年11月12日耗资49万港元回购7.2万股，回购价格 每股6.8-6.9港元。 ...